IP Library › Granted Patent US 12,297,459
Granted Patent B2
US 12,297,459 · App. 17/291,769 · Granted May 13, 2025

Porcine rotavirus

Inventors: Ad De Groof (Groesbeek, NL); Paul Vermeij (St. Anthonis, NL); Cornelia Maria Van der Hoek (Amsterdam, NL); Martin Deijs (Huizen, NL)
Assignee: Intervet Inc.
C12N7/00C07K14/005C12N2720/12321C12N2720/12322C12N2720/12334
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,459
App. No.
17/291,769
Granted
May 13, 2025
Kind
B2
Abstract

The present invention pertains to a novel rotavirus, especially an isolated virus, which is a member of the sub-species of porcine group B rotavirus (porcine RVB), causing diarrheal disease in pigs, to DNA fragments and corresponding proteins of the said virus, to vaccines on the basis of said virus, DNA and/or protein and to antibodies reactive with said virus and/or protein and diagnostic test kits for the detection of said virus.

Claims (19)

1. An isolated rotavirus which is a member of the sub-species of porcine group B rotaviruses genotype G12, which in its wild type form causes diarrhea in pigs, said virus being characterized in that it has a viral genome comprising an open reading frame having a nucleotide sequence corresponding to the nucleotide sequence depicted in SEQ ID NO: 1 or a nucleotide sequence having a level of identity of at least 90% therewith.

2. The isolated virus according to claim 1 , characterized in that the nucleotide sequence having a level of identity of at least 90% to the nucleotide sequence depicted in SEQ ID NO: 1 encodes an outer viral capsid glycoprotein VP7.

3. A nucleic acid fragment comprising an open reading frame, said open reading frame comprising at least 200 nucleotides, characterized in that said nucleic acid fragment has a nucleotide sequence that corresponds to a sequence having a level of identity of at least 90% to the nucleotide sequence depicted in SEQ ID NO: 1.

4. The nucleic acid fragment according to claim 3 , characterized in that the open reading frame encodes an outer viral capsid glycoprotein VP7.

5. The nucleic acid fragment according to claim 3 , characterized in that the open reading frame is under the control of a heterologous promoter.

6. A recombinant protein encoded by the open reading frame of the nucleic acid fragment according to claim 3 .

7. An outer viral capsid glycoprotein VP7 or a fragment thereof, characterized that it is a protein according to SEQ ID NO:2, or a protein having a level of identity of at least 93% therewith.

8. A vaccine for use in protecting against an infection caused by porcine group B rotavirus, characterized in that said vaccine comprises an immunogenically effective amount of a virus according to claim 1 , and a pharmaceutically acceptable carrier.

9. A vaccine for use in protecting against an infection caused by porcine group B rotavirus, characterized in that said vaccine comprises an immunogenically effective amount of a virus according to according to claim 6 and a pharmaceutically acceptable carrier.

10. A vaccine for use in protecting against an infection caused by porcine group B rotavirus, characterized in that said vaccine comprises an immunogenically effective amount an outer viral capsid glycoprotein VP7 according to claim 7 .

11. A method for protecting an animal against an infection caused by porcine group B rotavirus by systemically administering a vaccine according to claim 8 to the animal.

12. A virus according to claim 1 for use in the manufacture of a vaccine for protecting an animal against an infection caused by porcine group B rotavirus.

13. A recombinant protein according to claim 6 for use in the manufacture of a vaccine for protecting an animal against an infection caused by porcine group B rotavirus.

14. An outer viral capsid glycoprotein VP7 according to claim 7 for use in the manufacture of a vaccine for protecting an animal against an infection caused by porcine group B rotavirus.

15. A nucleic acid fragment according to any of the claim 3 for use in the manufacture of a vaccine for protecting an animal against an infection caused by porcine group B rotavirus.

16. A vaccine for use in protecting against an infection caused by porcine group B rotavirus, characterized in that said vaccine comprises a nucleic acid fragment according to claim 3 and a pharmaceutically acceptable carrier.

17. A method for protecting an animal against an infection caused by porcine group B rotavirus by systemically administering a vaccine according to claim 16 to the animal.

18. A method for protecting an animal against an infection caused by porcine group B rotavirus by systemically administering a vaccine according to claim 9 to the animal.

19. A method for protecting an animal against an infection caused by porcine group B rotavirus by systemically administering a vaccine according to claim 10 to the animal.

Assignments (4)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2021
From: DE GROOF, AD; VERMEIJ, PAUL
To: INTERVET INC.
Reel/Frame 056157/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2021
From: VAN DER HOEK, CORNELIA MARIA; DEIJS, MARTIN
To: ACADEMISCH MEDISCH CENTRUM
Reel/Frame 056158/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2021
From: ACADEMISCH MEDISCH CENTRUM
To: INTERVET INC.
Reel/Frame 056158/0377 →
Priority Claims (1)
EP 18205672 · Nov 12, 2018 · regional
Continuity (1)
Related Publication 20220220452A1 · Jul 14, 2022
References Cited (19)
CN 106459928A · 2017 [cited by applicant]
CN 107875379A · 2018 [cited by applicant]
EP 0235391B1 · 1992 [cited by applicant]
JP S63115825A · 1988 [cited by applicant]
RU 2443430C2 · 2012 [cited by applicant]
WO WO2015158798A1 · 2015 [cited by applicant]
WO WO2006099561A1 · 2017 [cited by applicant]
Genbank KX869732.1, submitted Jul. 2017:pdf 1. [cited by examiner]
Alekseev, et al, Genome Characterization of a Pathogenic Porcine Rotavirus B Strain Identified in Buryat Republic, Russia in 2015, Pathogens, 2018, pp. 46, vol. 7. [cited by applicant]
Kazufumi Kugo et al, Genetic diversity and classification of the outer capsid glycoprotein VP7 of porcine group B rotaviruses, Arch Virol, 2009, pp. 1785-1795, vol. 154, Springer. [cited by applicant]
Marthaler et al, Detection of substantial porcine group B rotavirus genetic diversity in the United States, resulting in a modified classification proposal for G genotypes, Virology, 2012, pp. 85-96, vol. 433, Elsevier. [cited by applicant]
Marthaler et al, Rapid detection and high occurrence of porcine rotavirus A, B, and C by RT-qPCR in diagnostic samples, ournal ofVirological Methods, 2014, pp. 30-34, vol. 209, Elsevier. [cited by applicant]
Entry date: 2017. XP002787684 retrieved from EBI accession No. Uniprot: ADA221SDV7. [cited by applicant]
XP002787683 retrieved from EBI accession No. UNIPROT: DOFYJ7, entry date: 2009. [cited by applicant]
XP002787471 retrived from EBI accession No. EMBL: AB490426, entry date: 2009. [cited by applicant]
XP002787472 retrieved from EBI accession No. EMBL: KX869732, entry date: 2017. [cited by applicant]
Briko, 2001, “Criteria for assessing the effectiveness of vaccination,” Medical scientific and practical portal, #03/01 [online], Apr. 2, 2001, [retrieved on Jun. 12, 2024]. Retrieved from the Internet:<URL: https://www… [cited by applicant]
Kuga et al., 2009, “Genetic diversity and classification of the outer capsid glycoprotein VP7 of porcine group B rotaviruses,” Arch. Virol., 154(11):1785-1795. [cited by applicant]
Yang et al., 2016 “Isolation and identification of one strain of porcine rotavirus,” Animal Husbandry & Veterinary Medicine, 48(9):32-37 (in Chinese with English abstract). [cited by applicant]